Alcohol Plays a Detrimental Role in the Prognosis of Hepatocellular Carcinoma Related to Steatotic Liver Disease.

Authors

Stefano Gitto, Alessandro Vitale, Gianluca Svegliati-Baroni, Giulio Marchesini, Francesco Paolo Russo, Luca Miele, Claudia Campani, Valentina Adotti, Martina Rosi, Francesco Vizzutti, Mariarosaria Marseglia, Andrea Martini, Angelo Sangiovanni, Giuseppe Cabibbo, Giacomo Zaccherini, Giorgia Ghittoni, Maria Di Marco, Francesco Giuseppe Foschi, Filomena Morisco, Sara Grasselli, Carlo Saitta, Francesca Romana Ponziani, Maurizia Rossana Brunetto, Donatella Magalotti, Francesco Azzaroli, Andrea Mega, Rodolfo Sacco, Gerardo Nardone, David Sacerdoti, Sara Boninsegna, Gianpaolo Vidili, Franco Trevisani, Edoardo G Giannini, Fabio Marra, Italian Liver Cancer (ITA.LI.CA) group

Published in

Liver cancer. Jul 02, 2026. Epub Jul 02, 2026.

Abstract

The recently adopted nomenclature of steatotic liver disease (SLD) introduces new diagnostic categories, including metabolic dysfunction-associated steatotic liver disease (MASLD), the intermediate metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD). However, their specific impact on the outcomes of hepatocellular carcinoma (HCC) remains unclear. This study aimed to evaluate how alcohol consumption influences prognosis in patients with SLD-related HCC.
We analyzed data from 2,864 HCC patients enrolled in the nationwide ITA.LI.CA database (2008-2022), stratifying those with SLD based on alcohol intake into MASLD, MetALD, and ALD. A comparator group with hepatitis B virus (HBV)-related HCC was also included. Multivariable Cox regression and competing risk analyses were employed to assess survival and cause-specific mortality.
Among SLD-related HCC, MASLD accounted for 47.1%, ALD 18.7%, and MetALD 7.2%. Patients with ALD showed the poorest liver function, more advanced tumor stage, and the highest mortality risk. Alcohol use progressively worsened prognosis from MASLD to ALD. MetALD and ALD were both associated with increased liver failure- and extrahepatic-related deaths compared to MASLD. In multivariable models, tumor burden, liver decompensation, and alcohol intake were significant predictors of mortality. Notably, metabolic comorbidities impacted prognosis predominantly in MetALD and ALD, suggesting an interaction between alcohol and systemic metabolic dysfunction.
Alcohol consumption exerts a dose-dependent detrimental effect on clinical outcomes in SLD-related HCC. These findings support a distinct prognostic stratification for HCC patients with MetALD and ALD, reinforcing the need for alcohol abstinence in individuals with metabolic liver disease.

PMID:
42583673
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.